KoBioLabs

KoBioLabs Goodwill/Assets

Goodwill to Total Assets Ratio of KoBioLabs (348150.KQ) as of Oct 18, 2026.

Goodwill/Assets

-

Last updated:

Goodwill to Total Assets Ratio of KoBioLabs is 2026 - . Goodwill to Total Assets Ratio of KoBioLabs was 2025 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KoBioLabs Stock analysis

What does KoBioLabs do? KoBioLabs Inc., headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on research and development of the microbiome, developing products such as Bioviom and Queens henna FOODOLOGY, as well as new microbiome drugs. It provides commissioned research services and sells its products domestically and internationally. Listed on 18 November 2020, KoBioLabs is active in both domestic and overseas markets. KoBioLabs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KoBioLabs stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio KoBioLabs since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's KoBioLabs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — KoBioLabs

All Key Metrics — KoBioLabs